104 results about "Human disease" patented technology

Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and / or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

The invention relates to the field of immunology, and discloses a polypeptide and a kit for distinguishing bovine and sheep brucella natural infection from a vaccine immune antibody. Polypeptides as shown in SEQ ID NO: 1 and SEQ ID NO: 2 are artificially synthesized and used as antigens to coat an elisa plate and a nitrocellulose membrane, and according to response characteristics of antibody level, identification and detection of natural infection and vaccine immunity of cattle and sheep populations are realized. The peptide fragment and the detection kit provided by the invention can make up the blank of identifying bovine and sheep brucella natural infection and immune antibodies. The method solves the problem that the antibody induced by the attenuated live vaccine and the naturally infected antibody are difficult to distinguish, provides a scientific basis for quarantine and purification of Brucella, and provides a technical guarantee for preventing human diseases and animals, advancing the mouth and protecting the body health of people.

Disclosed herein are methods for improving detection and monitoring of human diseases. The methods can be used to provide spatial and / or developmental localization of the source of each differential mutation within the body. The methods can also be used to generate a mutation map of a subject. And the mutation map can be used to monitoring state(s) of health of one or more tissues of a subject.

The invention discloses a method for establishing a hemophagocytic syndrome in-vitro cell disease model, and belongs to the technical field of biology. Based on human PBMC construction, the reaction of a human immune system can be truly reflected, experimental result deviation caused by species difference in an animal model is avoided, and a more accurate model basis is provided for research of human diseases. In addition to T cell over-activation, the HLH model of the present application has a clear key feature of NK cell reduction, which is HLH, accompanied by up-regulation of cytokines such as interferon-gamma and IL-10. The establishment process of the model is rapid and efficient, the experimental period is remarkably shortened, a large number of samples or drugs can be rapidly screened, the research efficiency is improved, and the conversion process from basic research to clinical application is accelerated. The method can be used for researching various mechanisms related to the HLH, is beneficial to more comprehensive understanding of pathogenesis of the HLH, and provides a theoretical basis for developing preliminary screening of targeted drugs.

The invention discloses a medicinal arc scraping therapy device prepared from a Chinese herbal medicine composition and a preparation method of the medicinal arc scraping therapy device, the medicinal arc scraping therapy device prepared from a plurality of different negative and positive Chinese herbal medicine raw material compositions is used for carrying out physical therapy on different human diseased organs in the scraping therapy process, and the medicinal arc scraping therapy device has the characteristics that the medicinal arc scraping therapy device takes effect immediately, has a remarkable effect and can control the treatment course.

Disclosed herein are engineered LSR sequences, compositions, and uses including in genome-editing systems and therapeutic compositions. The LSRs can facilitate nucleic acid recombination at particular attachment sites, using suitable donor sequences. The disclosed LSRs may be used to site-specifically recombine or integrate nucleic acid sequences for a variety of purposes, including treatment of human diseases.

The present disclosure provides methods of amplifying tissue samples derived from humans for purposes of treating certain diseases. The method comprises: isolating a small amount of associated tissue by biopsy or other tissue acquisition methods; the tissue is amplified in vitro, and meanwhile, natural functions are reserved; and re-implanting the amplified tissue to alleviate human disease. One example includes ex vivo expansion of human pancreatic islet tissue and reimplantation of the expanded cells into an individual with Type 1 diabetes for treatment and long term relief or cure of disease.

The present disclosure provides transgenic mice for use as mouse models, and methods related thereto. The transgenic mice described herein comprise a humanized mouse telomerase (hmTert) gene included in a background mouse germline that provides shortened telomeres capable of reproducing humans and various human disease states.

Provided are a novel bispecific antigen-binding antibody, an antigen-binding fragment thereof, and a Trop2 * HER2 bispecific antibody drug conjugate (Trop2 * HER2 Abs ADC) which comprise a Trop2-binding arm and an HER2-binding arm, are capable of simultaneously specifically binding to HER2 and Trop2, have a high binding affinity to HER2 and Trop2, can be endocytosed by cells expressing HER2 and / or Trop2, and can be used as an antigen-binding fragment of a Trop2 * HER2 bispecific antibody drug conjugate. Endocytosis of the two binding arms L has a synergistic effect; the Trop2 * HER2 Abs ADC can inhibit the growth of tumor cells expressing HER2 and / or Trop2 in vitro and in vivo, and the bispecific antibody can be used for preventing and treating human diseases related to HER2 and / or Trop2, such as cancers.

Methods of treating or preventing a disease resulting from a respiratory syncytial virus (RSV) infection in a human subject is disclosed. The methods disclosed include administering to the human subject a compound of Formula (I), or pharmaceutical composition including a compound of Formula (I). In certain embodiments, the compound is celgosivir.

Cyclopropyl N-[(S)-[3-[1-(2,2-difluoropropylcarbamoyl)-3-hydroxy-3-methyl- cyclobutyl]imidazo[1,2-b][1,2,4]triazin-6-yl]-[4- (trifluoromethyl)cyclohexyl]methyl]carbamate, or a pharmaceutically acceptable salt thereof, being a potent modulator of human IL-17 activity, is accordingly of benefit in the treatment and / or prevention of various human ailments, including inflammatory and autoimmune disorders.

N-[(S)-[3-[1-(2,2-difluoropropylcarbamoyl)-3-hydroxy-3-methyl- cyclobutyl]imidazo[1,2-b][1,2,4]triazin-6-yl]-[4-(trifluoromethyl)cyclohexyl]methyl]-4-5 methyl-1,2,5-oxadiazole-3-carboxamide, or a pharmaceutically acceptable salt and / or solvate thereof, being a potent modulator of human IL-17 activity, is accordingly of benefit in the treatment and / or prevention of various human ailments, including inflammatory and autoimmune disorders.

An effective treatment method for a broad variety of diseases in both animals and humans is disclosed. The method includes combining one or more vaccines with a treatment compound to enhance vaccine efficacy. The disclosed treatment compound does not act directly on the pathogen, and thus the organisms cannot readily develop resistance to the treatment. When a compound such as, but not limited to, the disclosed compound is used in conjunction with one or more vaccines, a synergistic effect is realized. The suggested compound is derived from a lipopolysaccharide (LPS) of gram negative bacteria. The treatment compound is combined with one or more appropriate vaccines and is administered early in the life of an animal to achieve a synergistic effect compared with the use of the treatment compound or the vaccine alone.

Pharmaceutical compositions and methods of using these compositions are disclosed that show efficacy in the treatment / amelioration of various human diseases, including cancer. The pharmaceutical composition comprises compounds that modulate the function of fatty-acid binding proteins that are used in combination with immunotherapy treatment that demonstrates synergistic efficacy to target and eliminate disease-associated antigens and / or cells.

Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).

A T cell receptor (TCR) plays a crucial role in adaptive immune response by recognizing specific antigens. In the context of cancer immunotherapy, TCR sequences may be engineered to target specific tumor antigens. In this study, hepatocellular carcinoma (HCC) was simulated in mice by binding to genetic alterations repeatedly observed in human diseases, and HCC-specific TCR was identified using single cell TCR-seq. The TCR convergence is observed in a mouse carrying HCC, indicating that the TCR specific to the HCC antigen initiates the expansion of CD4 + T cells. In order to further clarify the function of such HCC-specific TCRs, TCR expression vectors are designed and constructed, which can be used in a variety of in vitro and in vivo applications, including identification of specific peptide sequences for TCR recognition, manufacture of TCR engineered T cells, study of T cell function, and screening for potential immunotherapy. These findings are of great significance to the development of T cell-based cancer immunotherapies.

Provided herein are methods for the activation and expansion of genetically-modified Tcells, such as tumor infiltrating lymphocytes. In some cases, cells of the embodiments can be used for the therapeutic treatment of human diseases, such as cancer.

The present application provides a method for directional transfer of heterologous chromosomes, which comprises the following steps: artificially adding a functional intron containing a loxP sequence into a drug resistance gene, splitting the drug resistance gene into two parts with an overlapping region containing a loxP sequence, inserting the two parts of the drug resistance gene into target chromosomes of a donor species and a recipient species respectively (the two parts of the drug resistance gene undergo Cre / loxP site-specific recombination under the action of a Cre recombinase, and the drug resistance function is recovered), and realizing directional transfer of heterologous chromosomes by means of heterologous cell fusion. The method can be widely applied to gene function research, construction of human disease models, development of therapeutic antibodies, and pharmacological and pharmacodynamic tests.

The invention described herein provides a method of treatment for a disease in a human in need thereof, comprising administering to the human an rAAV viral particle comprising a polynucleotide encoding a therapeutic gene-of-interest, as described herein. The method can be used for delivering a gene of interest (GOI), such as a microdystrophin-encoding polynucleotide sequence, for the treatment of a disease, e.g., muscular dystrophy such as Duchenne muscular dystrophy (DMD).

The present application relates to a kind of construction method of atherosclerosis humanized mouse model, belong to genetic engineering and genetic modification technical field.The present application is first in ApoE and Ldlr double gene knockout mouse background and obtains NOD-4G gene knockout mouse by knockouting Prkdc and Il2rg gene in mouse, humanized atherosclerosis model is constructed by injecting human umbilical cord blood CD133+stem cell and high-fat feed feeding.Through to atherosclerosis degree analysis, it is found that the aorta and aortic root of the humanized atherosclerosis model constructed have a large number of plaque formation, and contain human CD45 + Leukocyte.This atherosclerosis humanized mouse model provides better animal genetic model for the analysis of the role of human immune cells in the occurrence and development of atherosclerosis disease, and has important significance for the research of human disease and the development of new therapy.

The invention provides compounds that modulate the activity of protein kinases that are associated with human diseases, disorders, and conditions. In particular, compounds of the invention inhibitTYK2, a member of the Janus Kinase (JAK) family of non -receptor protein kinases.

The invention belongs to the technical field of biology, and particularly relates to a scoliosis rat model construction method which comprises the following steps: S1, obtaining an experimental animal, removing the forelimb and the tail of the experimental animal, enabling the gravity direction of the experimental animal to be parallel to the spine, and obtaining a biped animal; s2, performing excision treatment on a deep paravertebral muscle group on one side of the biped animal to obtain an experimental animal with muscle mechanics imbalance; and S3, performing exercise load stimulation treatment on the experimental animal with muscle mechanics imbalance to obtain the scoliosis animal model. According to the method disclosed by the invention, the scoliosis animal model capable of highly simulating human disease characteristics is constructed by combining axial gravity load under a two-foot standing posture, structural and mechanical unbalance caused by directional unilateral deep paravertebral muscle excision and regular movement stimulation; the method can accurately and controllably induce scoliosis in a specific direction opposite to a muscle resection side, and has a wide application prospect.

The disclosure provides fusion proteins specific for both CD137 and GPC3, which fusion protein can be used to co-stimulate lymphocyte activation in a GPC3-target-dependent manner. Such fusion proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and / or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion proteins described herein as well as compositions comprising such fusion proteins. The present disclosure further relates to nucleic acid molecules encoding such fusion proteins and to methods for generation of such fusion proteins and nucleic acid molecules. In addition, the application discloses therapeutic and / or diagnostic uses of such fusion proteins as well as compositions comprising one or more of such fusion proteins.

This disclosure provides ungulate embryonic stem cells (ESCs) derived from the inner cell mass of pre-implantation blastocysts or pluripotent cells from embryos. From an agricultural and biomedical perspectives, the derivation of stable ESCs from domestic ungulates is important for genomic testing and selection, genetic engineering, and providing an experimental tool for studying human diseases. Cattle are one of the most important domestic ungulates that are commonly used for food and bioreactors.

Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).

The invention discloses a preparation method and application of autonomic ganglion organoid, and relates to the technical field of biology. The method comprises the following steps: 1) providing neural crest stem cells; 2) differentiating the neural crest stem cells into autonomic ganglion-like organs through the combined action of added external factors and internal factors; wherein the external factors comprise a bFGF (basic fibroblast growth factor), an IGF-1 (insulin-like growth factor), a BDNF (brain-derived neurotrophic factor), a GDNF (brain-derived neurotrophic factor), an NGF (nerve growth factor), an NT-3, an EGF (epidermal growth factor), Forskolin, a DAPT (diaminopropyltriethoxysilane), an insulin, a Transferrin, an Activin A and a BMP4 (bone morphogenetic protein 4); the addition of the intrinsic factors is that the following four transcription factors, namely Ascl1, Hand2, Phox2a and Phox2b, are overexpressed in the neural crest stem cells at the same time. The organoid prepared by the scheme contains various neurons similar to the autonomic ganglion in vivo, Schwann glial cells and satellite glial cells. The prepared autonomic ganglion organoid can be applied to research on development regulation of autonomic ganglions and occurrence and development mechanisms of various human diseases, development of therapeutic drugs and the like.

The invention provides a retina photosensitive neuronal lesion zebrafish model and a construction method thereof, and relates to the technical field of gene engineering. Wherein the sgRNA comprises a guide sequence which can specifically recognize and be combined with a nucleotide sequence shown as SEQ ID NO.4 in an elovl2 gene. The high specificity of the sgRNA ensures the precise targeted modification of the elovl2 gene, and obviously reduces the off-target risk. The genetic background of the constructed zebrafish model is clear, and the retinopathy phenotype can be reliably attributed to the lovl2 gene mutation, so that a stable biological tool which is highly similar to human diseases is provided for related disease research and drug screening.

The disclosure provides a fusion polypeptide specific for CD137 and GPC3, which fusion polypeptide may be useful for directing CD137 clustering and activation of GPC3-positive cancer cells. Such a fusion polypeptide may be useful in many pharmaceutical applications, for example, as an anticancer agent and / or immunomodulator for the treatment or prevention of human diseases, such as a variety of cancers. The disclosure also relates to methods of making the fusion polypeptide described herein, as well as compositions comprising such a fusion polypeptide. The disclosure further relates to nucleic acid molecules encoding such a fusion and nucleic acid molecules. Furthermore, the disclosure includes therapeutic and / or diagnostic uses of such a fusion polypeptide, as well as compositions comprising one or more such fusion polypeptides.